搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
57 分钟
Dewpoint’s big year ends with a bang and even bigger hopes for 2025
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses ...
The Pharma Letter
1 小时
Neuraxpharm buys narcolepsy drugs
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both ...
The Pharma Letter
3 小时
Dimerix enters deal with FUSO for DMX-200 Japan
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and ...
The Pharma Letter
4 小时
City Therapeutics appoints Andrew Orth as chief exec
City Therapeutics appoints Andrew Orth as CEO, leveraging his expertise in RNA and gene therapies as the company advances its ...
The Pharma Letter
4 小时
Novartis gene therapy poised to expand SMA treatment landscape
Swiss pharma giant Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 ...
The Pharma Letter
4 小时
Heart failure market set to grow strongly, says GlobalData
The heart failure market is projected to grow from $13.5 billion in 2022 to $33.7 billion by 2032, driven by new therapies, ...
The Pharma Letter
4 小时
Moderna struggles laid bare by CEO admissions
The challenge of maintaining the earlier growth achieved by US mRNA medicines specialist Moderna through its COVID vaccine ...
The Pharma Letter
4 小时
I-Mab pauses uliledlimab work, shifts to bispecific
I-Mab shifts focus to givastomig, a bispecific antibody for CLDN18.2-positive tumors, following positive early data and ...
The Pharma Letter
6 小时
Vertex has CF cornered, but won’t stop till every patient feels the same
Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space. How has ...
The Pharma Letter
6 小时
Denali suffers ALS drug failure in Phase II/III trial
Denali Therapeutics' DNL343 fails to meet endpoints in the HEALEY ALS study, marking a second clinical setback for the ...
The Pharma Letter
7 小时
FDA framework to advance AI models used for drug and biological filings
The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial ...
The Pharma Letter
2 小时
Positive top-line Phase IIa results for Metsera’s obesity drugMET-097i
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈